TIGIT and head and neck squamous cell carcinoma: Interestingly, blocking PD1/PD-L1 signaling was shown to increase the expression of TIGIT on Tregs in head and neck squamous cell carcinoma (HNSCC) patients (49), suggesting a resistant mechanism for αPD1 immunotherapy mediated by TIGIT.